TTI — Thiogenesis Therapeutics Income Statement
0.000.00%
- CA$31.85m
- CA$26.32m
- 28
- 12
- 50
- 20
Annual income statement for Thiogenesis Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | |
---|---|---|
Period Length: | 12 M | 12 M |
Source: | ARS | ARS |
Standards: | — | IFRS |
Status: | Final | Final |
Total Revenue | 0 | 0 |
Selling / General / Administrative Expenses | ||
Research And Development | ||
Unusual Expense / Income | ||
Total Operating Expenses | — | 5.21 |
Operating Profit | 0 | -5.21 |
Total Net Non Operating Interest Income / Expense | ||
Other Net Non Operating Costs | ||
Net Income Before Taxes | — | -5.06 |
Net Income After Taxes | — | -5.06 |
Net Income Before Extraordinary Items | ||
Net Income | — | -5.06 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||
Income Available to Common Shareholders Including Extraordinary Items | ||
Dilution Adjustment | ||
Diluted Net Income | 0 | -5.06 |
Diluted Weighted Average Shares | ||
Basic EPS Including Extraordinary Items | ||
Diluted EPS Including Extraordinary Items | ||
Diluted EPS Excluding Extraordinary Items | ||
Normalised Income Before Taxes | ||
Normalised Income After Taxes | ||
Normalised Income Available to Common Shareholders | ||
Diluted Normalised EPS | — | -0.129 |